Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Acquired by Raymond James & Associates

Raymond James & Associates raised its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 121.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,247 shares of the company’s stock after purchasing an additional 7,268 shares during the period. Raymond James & Associates owned 0.33% of Invesco Biotechnology & Genome ETF worth $872,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Creative Financial Designs Inc. ADV raised its holdings in shares of Invesco Biotechnology & Genome ETF by 6.6% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 3,347 shares of the company’s stock worth $220,000 after purchasing an additional 206 shares during the period. Kestra Advisory Services LLC raised its stake in shares of Invesco Biotechnology & Genome ETF by 4.2% in the 3rd quarter. Kestra Advisory Services LLC now owns 6,362 shares of the company’s stock valued at $363,000 after acquiring an additional 254 shares during the period. UBS Group AG lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 9.6% during the 3rd quarter. UBS Group AG now owns 94,250 shares of the company’s stock valued at $5,376,000 after acquiring an additional 8,266 shares in the last quarter. Penobscot Investment Management Company Inc. acquired a new position in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter valued at $562,000. Finally, Dakota Wealth Management boosted its position in Invesco Biotechnology & Genome ETF by 2.1% during the 3rd quarter. Dakota Wealth Management now owns 12,280 shares of the company’s stock worth $700,000 after purchasing an additional 250 shares during the period.

Invesco Biotechnology & Genome ETF Price Performance

NYSEARCA:PBE opened at $60.40 on Tuesday. The business’s 50-day moving average is $64.09 and its two-hundred day moving average is $61.84. The firm has a market capitalization of $229.53 million, a PE ratio of 16.61 and a beta of 0.92. Invesco Biotechnology & Genome ETF has a 12 month low of $52.47 and a 12 month high of $67.76.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.